Gonorrhoea: clinical features, diagnosis, treatment and prevention
On this page
01
Overview
Gonorrhoea is caused by Neisseria gonorrhoeae, a gram-negative intracellular diplococcus that infects the columnar and transitional epithelium of the urethra, cervix, rectum, pharynx and conjunctiva. It is one of the most common bacterial sexually transmitted infections worldwide and a major driver of pelvic inflammatory disease (PID), infertility, ectopic pregnancy, neonatal blindness and disseminated infection. Many infections — especially in women, and most pharyngeal and rectal infections — are asymptomatic, so the infection spreads silently while still causing damage.
Take specimens from every exposed site before giving antibiotics, treat promptly with a ceftriaxone-based regimen, test for chlamydia/HIV/syphilis, and treat the partners — treating the patient alone almost guarantees reinfection.
02
Learning objectives
- Recognise gonorrhoea by site: urethral, cervical, rectal, pharyngeal, ocular and disseminated.
- Choose the correct diagnostic test — NAAT for screening, culture for resistance surveillance.
- Prescribe current guideline treatment with correct adult, paediatric and pregnancy doses.
- Manage complications: PID, epididymo-orchitis, disseminated gonococcal infection and neonatal disease.
- Apply partner notification, abstinence advice and test-of-cure to prevent reinfection.
03
Organism and transmission
N. gonorrhoeae attaches to mucosa via pili and opacity proteins, invades epithelial cells and triggers intense neutrophilic inflammation — the source of the classic purulent discharge. Transmission is by vaginal, anal or oral sex, and vertically from mother to newborn during delivery. The organism has a remarkable capacity to develop antimicrobial resistance: penicillin, tetracyclines and fluoroquinolones have all been lost as reliable treatments in most of the world, which is why third-generation cephalosporins are now the backbone of therapy and culture with susceptibility testing matters more than ever. Infection does not produce durable immunity — repeated infections are the rule.
04
Clinical presentation by site
Scroll the table sideways on a smaller screen.
| Site | Incubation | Clinical features | Key complications |
|---|---|---|---|
| Urethra (men) | 2–7 days | Dysuria, profuse purulent yellow-green discharge, meatal erythema; may be mild or absent | Epididymo-orchitis, urethral stricture |
| Cervix (women) | 2–7 days (often silent) | Mucopurulent discharge, dysuria, lower abdominal pain, post-coital or intermenstrual bleeding; many asymptomatic | Pelvic inflammatory disease, infertility, ectopic pregnancy |
| Rectum | Variable; often silent | Anorectal pain, pruritus, tenesmus, bleeding or discharge | Proctitis; reservoir for reinfection |
| Pharynx | Usually silent | Asymptomatic, or mild sore throat with cervical lymphadenopathy | Persistence despite treatment — needs test-of-cure |
| Conjunctiva (neonate) | 2–5 days after birth | Severe purulent conjunctivitis with lid oedema | Corneal ulceration and blindness — an ophthalmic emergency |
In women, cervicitis is suggested by mucopurulent endocervical discharge or easy bleeding when swabbed. Because female infection is frequently asymptomatic, women often present late — with complications — rather than with early localising symptoms.
05
Complications
Pelvic inflammatory disease (PID)
Lower abdominal pain with cervical-motion, uterine or adnexal tenderness is PID until proven otherwise. Fever, tubo-ovarian abscess or peritonism needs admission. Each episode of PID raises the risk of tubal infertility and ectopic pregnancy.
Epididymo-orchitis
Unilateral scrotal pain and swelling in a sexually active young man; must be differentiated from testicular torsion — if torsion cannot be excluded within the window for surgical salvage (6 hours), explore surgically first.
Disseminated gonococcal infection (DGI)
From bacteraemic spread: fever, migratory polyarthralgia, tenosynovitis, sparse pustular skin lesions, then asymmetric septic arthritis (classically a knee or wrist). Endocarditis and meningitis are rare but life-threatening. DGI strains are often less pigmented and harder to culture from genital sites.
Neonatal disease
Ophthalmia neonatorum can destroy the cornea within days; neonates can also develop gonococcal sepsis, arthritis and meningitis.
06
Diagnosis
- NAAT (nucleic acid amplification test) on first-void urine or a genital swab — the most sensitive test; collect rectal and pharyngeal swabs from every exposed site, because a urine test alone misses extragenital infection.
- Gram stain of urethral discharge — intracellular gram-negative diplococci inside neutrophils are highly suggestive in symptomatic men (sensitivity is poor at the cervix, pharynx and rectum).
- Culture with antimicrobial susceptibility testing — essential for treatment failure, pharyngeal infection, disseminated disease, medico-legal cases and national resistance surveillance. Alert the laboratory: N. gonorrhoeae needs 5% CO2 and prompt plating.
- Always co-test for chlamydia, syphilis and HIV; do a pregnancy test in any woman who could be pregnant.
- In suspected DGI: blood cultures and synovial-fluid Gram stain, culture and NAAT.
07
Treatment
Scroll the table sideways on a smaller screen.
| Regimen | Dose (adult) | Paediatric | Notes and cautions |
|---|---|---|---|
| Ceftriaxone IM (first-line) | 500 mg IM as a single dose; 1 g IM if body weight over 150 kg | 25–50 mg/kg IM (max 500 mg, 1 g if over 45 kg) | Give with lidocaine to reduce injection pain; first-line in pregnancy; cover chlamydia separately |
| Doxycycline PO (added when chlamydia not excluded) | 100 mg twice daily for 7 days | Avoid under 8 years and in pregnancy | Tetracycline; photosensitivity, oesophagitis — take with water, avoid antacids; not for the gonococcus itself in resistant areas but covers co-infection |
| Cefixime PO (alternative where IM impractical) | 800 mg single dose | 8 mg/kg single dose | Oral alternative with rising resistance — culture and test-of-cure advised |
| Spectinomycin IM (cephalosporin allergy) | 2 g IM single dose | 40 mg/kg | No longer manufactured in many countries; poor for pharyngeal infection |
| Gentamicin IM (where neither is available, per national protocol) | 240 mg IM single dose | Specialist guidance only | Reserved; watch renal function and hearing |
Complicated infection
PID — ceftriaxone 500 mg IM single dose plus doxycycline 100 mg BD × 14 days plus metronidazole 400–500 mg BD × 14 days (anaerobic cover). Admit if pregnant, severely ill, tubo-ovarian abscess, or cannot tolerate oral therapy.
Epididymo-orchitis — ceftriaxone 500 mg IM single dose plus doxycycline 100 mg BD × 10–14 days (chlamydia co-coverage); add/adjust if enteric organisms possible in older men.
Disseminated infection — hospitalise: ceftriaxone 1 g IV/IM daily until 24–48 hours after clinical improvement, then step down to an oral agent guided by susceptibilities to complete at least 7 days. Drain purulent joints; evaluate for endocarditis and meningitis.
Neonatal ophthalmia — urgent systemic therapy (ceftriaxone 25–50 mg/kg IV/IM single dose, max 125 mg) plus saline eye irrigation; topical drops alone are inadequate. Parenteral treatment of the mother and partner is mandatory.
What NOT to use
Penicillins, fluoroquinolones (ciprofloxacin) and older tetracycline regimens are unreliable because of widespread resistance — a favourite exam trap. Never use leftover, shared or partial-course antibiotics; sub-lethal exposure drives resistance.
08
Special situations
- Pregnancy: ceftriaxone is safe and first-line; avoid doxycycline (use azithromycin 1 g single dose if chlamydia co-infection). Untreated gonorrhoea in pregnancy risks preterm delivery, premature rupture of membranes and neonatal infection.
- Cephalosporin allergy: confirm the history (many “penicillin allergies” are intolerance, not true IgE allergy); options include spectinomycin 2 g IM or dual therapy per specialist/microbiology advice with culture and susceptibility testing.
- HIV co-infection: treat identically, but ensure ART linkage and intensified partner services.
- Pharyngeal infection: use the guideline ceftriaxone dose and always arrange test-of-cure (culture preferred) because eradication is less reliable.
09
Partner management and prevention
- Partner notification: evaluate and presumptively treat partners from the last 60 days (or per national guidance) — index patients often delay sex, but untreated partners re-infect them.
- Abstinence: no sex until at least 7 days after treatment is completed and partners have been treated.
- Retesting: test-of-cure for pharyngeal infection (culture at 10–14 days); retest all patients around 3 months because reinfection is common.
- Prevention: consistent condom use, reduction of overlapping partnerships, and HIV prevention services (testing, PrEP/PEP assessment).
- Neonatal prophylaxis: erythromycin 0.5% eye ointment at birth per national policy for all newborns, with maternal STI screening and treatment.
10
Uganda context
Gonorrhoea syndromic management follows the Uganda Clinical Guidelines STI flowcharts, but where laboratory confirmation is available (NAAT or culture), use it — syndromic treatment over-treats and under-treats in equal measure. Ceftriaxone supply interruptions are a real problem; when IM ceftriaxone is unavailable, use the best national-protocol alternative and arrange test-of-cure rather than leaving the patient untreated. Integrate STI care with HIV testing — Uganda’s HIV epidemic makes dual testing standard of care at every STI visit. Report suspected treatment failure with culture and susceptibility testing to surveillance programmes.
11
Clinical scenario
Scenario — Recurrent “UTI”
A 26-year-old woman attends for the third time in 4 months with dysuria and has repeatedly been given co-trimoxazole with short-lived relief. Today she mentions a new partner 2 months ago. Speculum examination shows mucopurulent endocervical discharge and contact bleeding. Urinalysis is normal. NAAT on the cervical swab is positive for N. gonorrhoeae and C. trachomatis. Correct management: ceftriaxone 500 mg IM stat plus doxycycline 100 mg BD × 7 days, HIV/syphilis testing (offer PrEP counselling), treat the current partner with the same regimen, advise no sex until 7 days after both complete treatment, and book retesting at 3 months. The “recurrent UTI” was recurrent gonorrhoea — the antibiotics were never effective against the organism, and the partner was never treated.
Scenario — The sore knee
A 22-year-old man has a week of fevers, a sore wrist that moved to his knee, and a few scattered pustules on his hands. He is sexually active and recently had a treated “urethral infection”. This migratory pattern with tenosynovitis and pustular lesions is disseminated gonococcal infection: admit, take blood cultures and synovial fluid, start ceftriaxone 1 g IV daily, and re-examine the genital site — DGI strains may grow poorly from genital swabs even when blood and joint fluid are positive.
12
Key points
13
References
- Uganda Clinical Guidelines: management of STI syndromes.
- SlideShare: Gonorrhea — clinical features and management (Library reference.)
- CDC Sexually Transmitted Infections Treatment Guidelines (Library reference.)
- Davidson’s Principles and Practice of Medicine (Library reference.)
14
Further reading
For deeper study, compare this lesson with current guidance and standard references from recognised medical and public-health organisations.
For education only. Apply current Uganda Clinical Guidelines, local protocols and specialist advice in clinical practice.